Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 23OTHER 5NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3

Interventions

Radiotherapy 213Cisplatin 180Cyclophosphamide 168Doxorubicin 135Paclitaxel 125Vincristine 124Filgrastim 121Etoposide 103Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NETWORK × neratinib × Clear all
NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NSABP Foundation Inc

Phase 1/2 Completed
49 enrolled 17 charts
Breast

Breast Neoplasms

NCT01008150 2021-10-25

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

NSABP Foundation Inc

Phase 2 Completed
141 enrolled 16 charts
Breast

Breast Neoplasms

NCT01423123 2014-07-08

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

NSABP Foundation Inc

Phase 1 Completed
21 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡